Abstract 17155: Complications with Cardiac Perforation and Lead Dislodgement of the 5086 MRI Pacing Lead
As the MR-conditional Medtronic 5086 lead has been implanted, there were some reports that the 5086 lead demonstrated higher lead dislodgement and cardiac perforation compared with the 5076 lead. However, little is known regarding the rates of complications between the 5086 lead and the 5076 lead especially in asian populations.
The purpose of this study was to describe the incidence of lead-related complications including cardiac perforation and lead dislodgement of the 5086 lead compared to the 5076 lead and to investigate the clinical factors associated with development of cardiac perforation or lead dislodgement.
This study was a retrospective single center study. Consecutive 292 patients who underwent dual chamber pacemaker implantation using either 5076 (N=121) or 5086 lead (N=171) between January 2008 and March 2014 were enrolled in this study. Primary endpoint was incidence of cardiac perforation with pericardial effusion or cardiac tamponade within 30 days of implant. Secondary endpoint was combined incidence of cardiac perforation or lead dislodgement.
Primary outcome occurred in 3 patients with the 5806 lead (1.8%) and no patient with the 5076 lead (0.0%) (p=0.269). Lead dislodgement occurred in 9 patients with the 5806 lead (5.3%) and 5 patient with the 5076 lead (4.1%) (p=0.784) (Table1). There was no difference in the incidence of secondary endpoint between groups (7.0 vs 4.1%, p=0.447). On logistic regression analysis after multivariate adjustment, factors associated with an increased risk for dislodgement and cardiac perforation included heart failure, taking a rivaroxaban, and location of atrial lead other than right atrial appendage (Table2).
Compared with the 5076 lead, the rate of cardiac perforation and lead dislodgement was not significantly higher with the 5086 MRI lead in asian population. Cardiac perforation and lead dislodgements occured more often in patient with heart failure, taking a rivaroxaban, and unusual location of atrial lead.
Author Disclosures: J. Choi: None. J. Kim: None. U. Jo: None. C. Kwon: None. W. Lee: None. Y. Kim: None. G. Nam: None. K. Choi: None. Y. Kim: None.
- © 2014 by American Heart Association, Inc.